Cipher Pharmaceuticals (TSE:CPH) Stock Price Down 7.9%

Cipher Pharmaceuticals Inc. (TSE:CPHGet Free Report) (NASDAQ:CPHR) shares fell 7.9% on Monday . The company traded as low as C$8.08 and last traded at C$8.20. 120,512 shares changed hands during trading, an increase of 205% from the average session volume of 39,448 shares. The stock had previously closed at C$8.90.

Analyst Upgrades and Downgrades

Separately, Citigroup boosted their price target on shares of Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th.

View Our Latest Analysis on Cipher Pharmaceuticals

Cipher Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.44, a current ratio of 9.19 and a quick ratio of 2.67. The stock has a market cap of C$201.04 million, a P/E ratio of 7.69 and a beta of 0.97. The company’s 50 day simple moving average is C$7.33 and its 200 day simple moving average is C$6.00.

Cipher Pharmaceuticals (TSE:CPHGet Free Report) (NASDAQ:CPHR) last issued its earnings results on Thursday, March 14th. The company reported C$0.41 EPS for the quarter, beating the consensus estimate of C$0.15 by C$0.26. Cipher Pharmaceuticals had a net margin of 96.32% and a return on equity of 28.19%. The firm had revenue of C$6.70 million during the quarter, compared to the consensus estimate of C$7.31 million. As a group, equities analysts forecast that Cipher Pharmaceuticals Inc. will post 0.6156889 earnings per share for the current year.

About Cipher Pharmaceuticals

(Get Free Report)

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.

See Also

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with's FREE daily email newsletter.